Biofrontera (NASDAQ:BFRI) Raised to Hold at Zacks Research

Biofrontera (NASDAQ:BFRI) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the stock. Wall Street Zen raised shares of Biofrontera to a “hold” rating in a research report on Saturday, July 18th. Weiss Ratings upgraded Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold”.

Biofrontera Stock Performance

Shares of BFRI stock opened at $1.22 on Monday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.09 and a current ratio of 1.20. Biofrontera has a 52 week low of $0.55 and a 52 week high of $1.27. The company’s 50 day moving average price is $1.03 and its two-hundred day moving average price is $0.96. The company has a market capitalization of $15.62 million, a P/E ratio of -1.26 and a beta of 0.78.

Biofrontera (NASDAQ:BFRI) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.29). Biofrontera had a negative net margin of 25.66% and a negative return on equity of 515.34%. The company had revenue of $10.08 million during the quarter, compared to analyst estimates of $10.25 million. On average, analysts expect that Biofrontera will post -0.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Biofrontera

A hedge fund recently raised its stake in Biofrontera stock. Rosalind Advisors Inc. raised its holdings in shares of Biofrontera Inc. (NASDAQ:BFRI) by 51.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 976,448 shares of the company’s stock after acquiring an additional 332,055 shares during the quarter. Biofrontera makes up approximately 0.3% of Rosalind Advisors Inc.’s holdings, making the stock its 27th biggest position. Rosalind Advisors Inc. owned approximately 9.63% of Biofrontera worth $695,000 at the end of the most recent quarter. 10.08% of the stock is owned by hedge funds and other institutional investors.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.